Allspring Global Investments Holdings LLC Sells 1,163 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Allspring Global Investments Holdings LLC cut its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 34.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,229 shares of the company’s stock after selling 1,163 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Omnicell were worth $84,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in OMCL. State of Alaska Department of Revenue grew its holdings in Omnicell by 403.6% during the third quarter. State of Alaska Department of Revenue now owns 28,149 shares of the company’s stock worth $1,267,000 after buying an additional 22,559 shares in the last quarter. Maryland State Retirement & Pension System purchased a new position in shares of Omnicell in the 3rd quarter worth approximately $750,000. SFE Investment Counsel grew its holdings in shares of Omnicell by 5.3% in the third quarter. SFE Investment Counsel now owns 11,745 shares of the company’s stock valued at $529,000 after acquiring an additional 589 shares in the last quarter. New York State Teachers Retirement System increased its position in shares of Omnicell by 5.9% during the third quarter. New York State Teachers Retirement System now owns 64,147 shares of the company’s stock valued at $2,889,000 after acquiring an additional 3,584 shares during the last quarter. Finally, Strs Ohio lifted its holdings in Omnicell by 50.0% during the third quarter. Strs Ohio now owns 3,900 shares of the company’s stock worth $175,000 after acquiring an additional 1,300 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on OMCL. Barclays assumed coverage on Omnicell in a research report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 target price for the company. Benchmark decreased their price objective on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating for the company in a report on Friday, February 9th. Finally, Wells Fargo & Company dropped their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus price target of $42.20.

Omnicell Trading Down 1.7 %

Shares of Omnicell stock opened at $27.40 on Tuesday. The stock has a market capitalization of $1.26 billion, a P/E ratio of -60.89 and a beta of 0.76. Omnicell, Inc. has a 52-week low of $25.69 and a 52-week high of $77.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.52. The stock’s 50-day simple moving average is $27.64 and its 200 day simple moving average is $32.04.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. The firm had revenue of $258.85 million during the quarter, compared to the consensus estimate of $256.00 million. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. As a group, research analysts anticipate that Omnicell, Inc. will post 0.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.